Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed…
Read More
For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise…
Read More
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin…
Read More
In recent years, interest in the therapeutic potential of psychedelics — including psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) — has surged. Clinical trials have increasingly reported…
Read More
If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about…
Read More
Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice…
Read More
For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma,…
Read More
The current state of the mental health system is a conversation that echoes in the halls of policy-making, the corners of social advocacy, and within the private struggles of individuals…
Read More
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and…
Read More
Enveric Biosciences recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued…
Read More
